Ionut-gabriel Funingana
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients.
Journal: Frontiers in oncology
Published: December 16, 2024
Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models.
Journal: bioRxiv : the preprint server for biology
Published: November 28, 2024
Coordinated protein modules define DNA damage responses to carboplatin at single-cell resolution in human ovarian carcinoma models.
Journal: Cell reports. Medicine
Published: October 30, 2024
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: September 02, 2024
Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Journal: Nature communications
Published: September 26, 2023
Predicting resistance to chemotherapy using chromosomal instability signatures.
Journal: Nature genetics
Published: July 21, 2023
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
Journal: Nature communications
Published: March 02, 2023
Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors.
Journal: Seminars in immunopathology
Published: October 31, 2022
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Journal: Nature communications
Published: October 21, 2022
Radiomic and Volumetric Measurements as Clinical Trial Endpoints-A Comprehensive Review.
Journal: Cancers
Published: September 14, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 06, 2022
Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.
Journal: Frontiers in oncology
Published: February 02, 2022
Last Updated: 09/26/2026